Stimulation of the in Vivo Production of Very Low Density Lipoproteins by Apolipoprotein E Is Independent of the Presence of the Low Density Lipoprotein Receptor*

Bas Teusink‡†‡, Arjen R. Mensenkamp†, Hans van der Boom‡, Folkert Kuipers§, Ko Willems van Dijk‡ and Louis M. Havekes†††‡‡‡‡

From the ‡TNO Prevention and Health, Gaubius Laboratory, NL-2301 CE Leiden, The Netherlands, †Center for Liver, Digestive and Metabolic Diseases, Laboratory of Pediatrics, University Hospital Groningen, 9713 GZ Groningen, The Netherlands, and Departments of ‡Human and Clinical Genetics, ††Cardiology, and §§Internal Medicine, Leiden University Medical Center, 2300 RA Leiden, The Netherlands

**This work was supported by Dutch Heart Foundation Grants NHS 96011 and 97067. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1724 solely to indicate this fact.

‡ To whom correspondence should be addressed: TNO Prevention and Health, Gaubius Laboratory, P. O. Box 2215, NL-2301 CE Leiden, The Netherlands. Tel.: 31-71-5181428; Fax: 31-71-5181904; E-mail: B.Teusink@pg.tno.nl.

† The abbreviations used are: apo, apolipoprotein; LDL, low density lipoprotein; LDLr, low density lipoprotein receptor; TG, triglyceride; VLDL, very low density lipoprotein; SDS-PAGE, SDS-polyacrylamide gel electrophoresis.

Apolipoprotein (apo) E stimulates the secretion of very low density lipoproteins (VLDLs) by an as yet unknown mechanism. Recently, a working mechanism for apoE was proposed (Twisk, J., Gillian-Daniel, D. L., Tebon, A., Wang, L., Barrett, P. H., and Attie, A. D. (2000) J. Clin. Invest. 105, 521–532) in which apoE prevents the inhibitory action of the low density lipoprotein receptor (LDLr) by binding to it. We have first tested whether this newly described effect of the LDLr on VLDL secretion, obtained in vitro, is also observed in vivo. In LDLr knockout mice (LDLr−/−), the production of VLDL triglycerides and apoB was 30% higher than that in controls. Also the ratio of apoB100/apoB48 secretion was increased in the LDLr−/− mice. The composition of nascent VLDL was similar in both strains. To test whether the action of apoE depends on the presence of the LDLr, VLDL production was measured in LDLr−/− and apoE−/− LDLr−/− mice. Deletion of apoE on a LDLr−/− background still caused a 50% decrease of VLDL triglycerides and apoB production. The composition of nascent VLDL was again similar for both strains. We conclude that the effect of apoE on hepatic VLDL production is independent of the presence of the LDLr.

In transgenic rabbits expressing human apoE3 (6). Hepatic overexpression of apoE2, apoE3, and apoE4 all stimulated VLDL secretion (7–9). In contrast, the mutant isoform apoE3-Leiden is not capable of stimulating VLDL secretion (10).

The mechanism by which apoE affects VLDL assembly and secretion is poorly understood. A recent in vitro study by Twisk et al. (11) offered a potential mechanism by which apoE might affect VLDL secretion. These authors studied the role of the LDL receptor (LDLr) in production of VLDL. Experiments in cultured hepatocytes of LDLr−/− and control mice showed that LDLr−/− hepatocytes had a strongly increased apoB secretion. This was explained in part by a decreased intracellular degradation of apoB protein. It was concluded that the LDLr binds nascent apoB intracellularly during the course of VLDL assembly, thereby promoting its intracellular degradation. Because apoE and apoB are both ligands for the LDLr, it was suggested that apoE’s stimulatory action on VLDL secretion might occur by preventing apoB from binding to the LDLr.

In this study, we tested the hypothesis that the effect of apoE on VLDL secretion is LDLr-dependent. After verification that the reported in vitro effects of the LDLr can also be observed in the in vivo situation, we tested whether the effect of apoE is LDLr-dependent by knocking out apoE on a LDLr-deficient background. Our results confirm that the LDLr modulates the VLDL production rate in vivo, but they also clearly indicate that the effect of apoE on VLDL production is independent of the presence of the LDLr.

**EXPERIMENTAL PROCEDURES**

**Animals**—All mice were housed under standard conditions with free access to water and regular laboratory chow. For the comparison between wild type and LDLr−/− mice, male mice with a C57BL/6 background were used. Male animals were also used for comparison of apoE−/− LDLr−/− mice with LDLr+/+ mice. Because the apoE−/− LDLr−/− double knockout mice were on a mixed background of C57BL/6 and 129, LDLr−/− mice on the same mixed genetic background as the double knockout mice were used in these experiments as controls. All experiments were approved by the institutional animal care committee.

**VLDL Production and Composition**—The in vivo VLDL production was measured after intravenous administration of 500 mg/kg Triton WR1339 as described previously (4, 12). To measure de novo synthesis of VLDL apoB, 100 μCi of 35S-Tran label (ICN, Zoetermeer, The Netherlands) was injected i.v. 30 min before Triton WR1339 injection. Blood samples were withdrawn from the tail at regular intervals after Triton WR1339 injection. At t = 120 min, an additional large blood sample was withdrawn via the orbital plexus. In each sample, plasma triglycerides (TGs) were determined, and the rate of triglyceride accumulation in plasma was taken as the in vivo rate of VLDL TG production.

From the large blood sample at t = 120 min after Triton WR1339 administration, 200 μl of plasma was brought to 1.063 g/ml with potas-
sium bromide in a volume of 2 ml, transferred to SW41 centrifuge tubes, and layered with a 1.006 g/ml salt solution. After 16 h of centrifugation at 37,000 rpm and 4°C, the VLDL fraction was carefully removed by pipetting off 1.2 ml. ApoB in 0.2 ml of this VLDL fraction was precipitated with isopropanol (13), dissolved in 20% (w/v) SDS, and counted for assessment of total VLDL apoB production. Pilots with blood samples taken at 1/h1005 min after Triton WR1339 administration showed that basal activity was less than 10% of the value at 1/h120 min, and therefore the 1/h120 min point was taken as the total de novo VLDL apoB production. In the remaining VLDL, triglycerides, phospholipids, and cholesterol were measured with commercially available kits as described previously (4). This composition of VLDL is a mixture of VLDL that circulated before administration of Triton WR1339 and nascent VLDL produced during the 2-h period after Triton WR1339 administration. To obtain the composition of nascent VLDL, the contribution of circulating VLDL was determined and corrected for, as described previously (14).

For determination of apoB100 and apoB48 production, an aliquot of the blood samples at 1/h1 and 1/h120 min after Triton WR1339 administration (10 μl) was delipidated by 1.8 ml of −20 °C diethyl ether:methanol (1:1), and, after centrifugation in an Eppendorff centrifuge (13,000 rpm, 10 min), the pellet was dissolved in sample buffer for SDS-PAGE analysis on a 5% (w/v) polyacrylamide gel. A volume corresponding to 5 μl of plasma was loaded onto the gel. The gel was fixed by Coomassie staining (BioSafe Coomassie; Bio-Rad) and dried overnight between two cellophane sheets using a GradiDry gel drying solution (Gradipore). After drying, one sheet was carefully removed, and the uncovered part of the gel was autoradiographed with phosphoimager technology.

Results

Effect of the LDL Receptor on VLDL Secretion in Vivo—First we tested whether the LDLr affects the VLDL secretion rate in vivo. Hepatic VLDL triglyceride and apoB production rates were measured by intravenous injection of 35S-Tran label and Triton WR1339 in 4-h-fasted mice. As shown in Fig. 1A, LDLr−/− mice showed a 30% increase in the triglyceride production rate as compared with wild type animals (162 ± 42 and 211 ± 12 μmol·kg−1·h−1 for wild type and LDLr−/− animals, respectively; p < 0.005). Total apoB production (Fig. 1B) was also significantly increased by ~30% in LDLr−/− mice as compared with wild type mice (100 ± 19% and 132 ± 42% for wild type and LDLr−/− mice, respectively; p < 0.05). We also measured the de novo synthesis rate of B100 and B48 by SDS-PAGE analysis of plasma collected 1 and 120 min after Triton WR1339 injection (Fig. 1C). No significant differences could be observed between the LDLr−/− and wild type mice for apoB100 and apoB48 production rates, although the former...

![Fig. 1. VLDL production in C57BL/6 and LDLr−/− mice measured by 35S-Tran label and Triton WR1339 administration. A, accumulation of triglycerides in plasma. C57BL/6 mice; LDLr−/− mice. B, total VLDL apoB secretion. VLDL was isolated 2 h after Triton WR1339 injection, and label incorporation in apoB was counted after isopropanol precipitation. C, apoB100 and apoB48 production as analyzed by SDS-PAGE analysis of plasma. Plasma from 1 and 120 min after Triton WR1339 injection was delipidated and subjected to SDS-PAGE analysis. The black bars indicate the average label incorporation in the apoB100 and apoB48 bands. For B and C, label incorporation was normalized to the B100 incorporation in the C57BL/6 mice.](http://www.jbc.org/doi/10.1074/jbc.M800550200)
The rate of total apoB production was significantly lower in the LDLr−/− mice compared with the wild type mice (53 ± 17% and 100 ± 39% for apoE−/− and apoE2−/− mice, respectively; p = 0.01). In Fig. 3C, SDS-PAGE analysis of plasma collected 1 and 120 min after Triton WR1339 administration is shown for the apoE−/− LDLr−/− double knockout mice and the LDLr−/− mice. Most strikingly, apoB100 production in the apoE−/− LDLr−/− mice was severely diminished to only 10% of that of the LDLr−/− mice.

In Fig. 4, the average composition of nascent and circulating VLDL is shown. Because of the high lipid levels in apoE−/− LDLr−/− mice before Triton WR1339 injection, the nascent VLDL composition is calculated using the differences in lipids between total VLDL 2 h after Triton WR1339 administration and the circulating VLDL lipid content (i.e. the lipids present before Triton WR1339 administration). In both mouse models, nascent VLDL was rich in triglycerides. Large differences were found in circulating VLDL: VLDL of the apoE−/− LDLr−/− mice contained only 7% TGs as compared with 50% TGs in the LDLr−/− mice.

DISCUSSION

In this study, we have tested the hypothesis that the effect of apoE on VLDL secretion is mediated via intracellular interaction with the LDL receptor. If this hypothesis were true, we reasoned that the 50% reduction of VLDL secretion as observed in the apoE−/− mouse compared with the wild type mice (4, 5) should not be observed on a LDLr−/− background. Fig. 3 shows that the effect of deleting apoE in reducing VLDL secretion was independent of the LDL receptor: a 50% reduction of both VLDL apoB and TGs was observed in the apoE−/− LDLr−/− mouse as compared with the LDLr−/− controls.

The conclusion that apoE acts on the VLDL assembly pathway irrespective of the presence of the LDL receptor is indirectly supported by other recent studies. On one hand, it was shown that apoE2, a variant of apoE that binds poorly to lipoprotein receptors (15), is still capable of stimulating VLDL secretion (3, 7, 9). On the other hand, truncation of apoE at the C-terminal lipid-binding domain abolishes the stimulatory effect of apoE on VLDL secretion (16, 17). This truncated form of apoE is properly transcribed and detectable in plasma associated with VLDL particles, and it still contains an intact LDLr binding domain as judged by rescue from hyperlipidemia in apoE−/− mice. Thus, if competition of apoE with apoB for binding to the LDLr was the mechanism of apoE’s action on VLDL secretion, the truncated apoE protein should still be able to increase VLDL secretion, whereas apoE2 should not be able to do so. Because the opposite is observed, we conclude that lipid binding, rather than receptor binding, is important for the stimulation of VLDL production by apoE.

Although apoE does not act via the LDL receptor, we did confirm in vivo that absence of the LDL receptor enhances VLDL apoB secretion as described previously for mouse hepatocytes (11). Thus, LDLr deficiency leads to a 30% increase in VLDL apoB production. Also, the rate of VLDL TG secretion was increased by 30% in LDLr−/− mice. The effects of the LDL receptor on VLDL apoB100 and apoB48 secretion were too small for our analysis to give significant differences. However, we found a significant increase in the ratio of secreted apoB100/apoB48 particles in the LDLr−/− mice. Thus, although the effect of the LDLr on VLDL apoB production in vivo is much smaller than that observed in vitro, it is in line with the previous in vitro observation that apoB100 secretion was increased 3–4-fold, and apoB48 was increased only 1.5–2-fold (11).

It has been reported that the genetic background can have a large impact on the rate of VLDL secretion (18). Because the apoE−/− LDLr−/− mice were on a mixed background of C57BL/6 and 129, we used LDLr−/− mice that were on the same mixed background. Our data confirm the impact of genetic background: when the rate of VLDL TG secretion is compared between the LDLr−/− mice on the two genetic backgrounds used in this study, the mice on a C57BL/6 background clearly had a higher VLDL TG secretion as compared with mice on the mixed background (211 ± 12 and 132 ± 39 μmol·kg⁻¹·h⁻¹, respectively).

The composition of nascent VLDL was similar for all mouse models tested, comprising ~70–75% triglycerides (Figs. 2 and 4). The TG content of the apoE−/− LDLr−/− mice was higher, i.e. 88%, but this is likely the result of the large contribution of circulating VLDL to the total VLDL fraction after Triton WR1339 administration. In particular, the cholesterol content of nascent VLDL is prone to large error because of the enor-
mouse models, e.g. the VLDLr−/− LDLr−/− mouse (14) and the apoE−/− mouse (4), nascent VLDL invariably contained ~65–80% triglycerides. This contrasts with studies in humans or in vitro systems. Compartmental modeling of apoB lipoprotein metabolism in humans invariably requires the input of particles into the plasma compartment ranging from large buoyant VLDL to LDL (21–23). Also, in in vitro experiments, the size (i.e. triglyceride content) of the lipoprotein particles produced varies and appears to be related to lipid availability (for review, see Ref. 24), although it has been suggested that lipolytic activity in the medium may account for at least some of the observed effects (25). We2 and others (26) have verified that catabolism of VLDL is completely blocked by Triton WR1339 administration, thus the composition of the VLDL that subsequently accumulates should be a direct measure of the composition of nascent VLDL. Therefore, we conclude that in contrast to the human situation, mice secrete VLDL rather homogeneously as triglyceride-rich particles. It therefore appears that in mice, the rate of VLDL production is regulated not so much by VLDL composition as by particle number, i.e. by degradation of nascent apoB protein and/or pre-VLDL particles during the second stage of VLDL assembly (24, 27). The large differences in the TG content of circulating VLDL as opposed to nascent VLDL (Figs. 2 and 4) reflect differences in VLDL catabolism (10).

We observed an unexpected effect of combined apoE and LDLr deficiency on the secretion of apoB100 particles: in the apoE−/− LDLr−/− mice, the secretion of apoB100 was reduced to only 10% of that in LDLr−/− mice. In apoE−/− mice, apoB100 production is at most 50% lower (5, 7), indicating that the severely reduced apoB100 production is a specific effect of combined apoE and LDLr deficiency. At this moment, we can only speculate on the mechanism that underlies this striking observation. Rather, we would like to discuss some fundamental differences between B100- and B48-containing lipoproteins that may be relevant in rationalizing our observations.

ApoB48 does not bind to the LDLr but rather requires the
LDLr-related protein for endocytosis (28, 29). LDLr-related protein-mediated uptake of lipoproteins depends on apoE (30). Therefore, in the apoE−/− mouse, the LDLr and the LDLr-related protein are not able to take up apoB48 particles. However, secretion of apoB48 particles by the liver still continues (5, 7). Because the rate of apoB48 particle secretion should equal the rate of apoB48 particle uptake in steady state, this implies that other receptors should be present to clear these apoB48 particles. One receptor may be the recently cloned LDLr-related protein that are clearly involved in lipoprotein uptake are thus required for VLDL uptake—LDLR−/− mice are the result of some unknown feed-forward mechanism to maintain steady state and prevent unstrained accumulation of apoB100 particles in the circulation. Such a feedback on VLDL secretion is only hypothetical at this moment; yet it becomes apparent that factors such as apoE and the LDLr that are clearly involved in lipoprotein uptake are also involved in VLDL production. The concept of hepatic VLDL production as a merely substrate-driven process (32) thus requires considerable sophistication.

Acknowledgments—We thank Elly de Wit for help with SDS-PAGE analysis and Peter Voshol for help with statistical analysis.

REFERENCES

1. Mahley, R. W., and Ji, Z. S. (1999) J. Lipid Res. 40, 1–16
2. Jong, M. C., Dahlmans, V. E., Hofker, M. H., and Havekes, L. M. (1997) Biochem. J. 328, 745–750
3. de Beer, F., van Dijk, K. W., Jong, M. C., van Vark, L. C., van Der Zee, A., Hofker, M. H., Fallaux, F. J., Hoeben, R. C., Smeek, A. H., and Havekes, L. M. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 1800–1806
4. Kuipers, F., Jong, M. C., Lin, Y., Eck, M., Havinga, R., Bloks, V., Verkade, H. J., Hofker, M. H., Moshage, H., Berkel, T. J., Vonk, R. J., and Havekes, L. M. (1997) J. Clin. Invest. 100, 2915–2922
5. Mensenkamp, A. R., Jong, M. C., van Goor, H., van Luyn, M. J., Bloks, V., Havinga, R., Voshol, P. J., Hofker, M. H., van Dijk, K. W., Havekes, L. M., and Kuipers, F. (1999) J. Biol. Chem. 274, 35711–35718
6. Huang, Y., Ji, Z. S., Brecht, W. J., Rall, S. C., Taylor, J. M., and Mahley, R. W. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 2952–2959
7. Maugeais, C., Tietge, U. J., Tsukamoto, K., Glick, J. M., and Rader, D. J. (2000) J. Lipid Res. 41, 1673–1679
8. Tsukamoto, K., Maugeais, C., Glick, J. M., and Rader, D. J. (2000) J. Lipid Res. 41, 253–259
9. Tsukamoto, K., Smith, P., Glick, J. M., and Rader, D. J. (1997) J. Clin. Invest. 100, 107–114
10. Mensenkamp, A. R., Teusink, B., Baller, J. F. W., Wolters, H., Havinga, R., Willems van Dijk, K., Havekes, L. M., and Kuipers, F. (2001) Arterioscler. Thromb. Vasc. Biol. 21, in press
11. Twisk, J., Gillian-Daniel, D. L., Tebon, A., Wang, L., Barrett, P. H., and Attie, A. D. (2000) J. Clin. Invest. 105, 521–532
12. Jong, M. C., Dahlmans, V. E., van Gorp, P. J., Breuer, M. L., Mol, M. J., van Der Zee, A., Frants, R. R., Hofker, M. H., and Havekes, L. M. (1996) Arterioscler. Thromb. Vasc. Biol. 16, 934–940
13. Egusa, G., Brady, D. W., Grundy, S. M., and Howard, V. B. (1983) J. Lipid Res. 24, 1261–1267
14. Tacken, P. J., Teusink, B., Jong, M. C., Harats, D., Havekes, L. M., van Dijk, K. W., and Hofker, M. H. (2000) J. Lipid Res. 41, 2055–2062
15. Mahley, R. W. (1988) Science 240, 622–630
16. Kypreos, K. E., Teusink, B., Willems, V. D., Havekes, L. M., and Zannis, V. I. (2001) J. Lipid Res. 42, 253–265
17. Kypreos, K. E., Willems van Dijk, K., Van der Zee, A., Havekes, L. M., and Zannis, V. I. (2001) J. Biol. Chem. 276, 19778–19786
18. Voyiaziakis, E., Ko, C., O'Rourke, S. M., and Huang, L. (1999) J. Lipid Res. 40, 2094–2092
19. van Dijk, K. W., van Vlijmen, B. J., De Winther, M. P., van hof, B., van Der Zee, A., van Der Boom, H., Havekes, L. M., and Hofker, M. H. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 2945–2951
20. Ishibashi, S., Herz, J., Maeda, N., Goldstein, J. L., and Brown, M. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4431–4435
21. Packard, C. J. (1999) Curr. Opin. Lipidol. 10, 237–244
22. Packard, C. J., Demant, T., Stewart, J. F., Bedford, D., Caslake, M. J., Schwertfiger, G., Bedynk, A., Shepherd, J., and Seidel, D. (2000) J. Lipid Res. 41, 305–318
23. Packard, C. J., and Shepherd, J. (1997) Arterioscler. Thromb. Vasc. Biol. 17, 3542–3556
24. Davis, R. A. (1999) Biochim. Biophys. Acta 1440, 1–31
25. Arrol, S., Mackness, M. I., and Darrington, P. N. (2000) Atherosclerosis 150, 255–264
26. Aalto-Setala, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechnier, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., and Breslow, J. L. (1992) J. Clin. Invest. 90, 1889–1900
27. Olafsson, S. O., Asp, L., and Boren, J. (1999) Curr. Opin. Lipidol. 10, 341–346
28. Rohlmann, A., Gotthardt, M., Hammer, R. E., and Herz, J. (1998) J. Clin. Invest. 101, 689–695
29. Veniant, M. M., Zlot, C. H., Walzem, R. L., Pierotti, V., Driscoll, R., Dichek, D., Herz, J., and Young, S. G. (1998) J. Clin. Invest. 102, 1559–1568
30. Linton, M. P., Hasty, A. H., Bhaera, V. R., and Fazio, S. (1998) J. Clin. Invest. 101, 1726–1736
31. Brown, M. L., Ramprasad, M. P., Umeda, P. K., Tanaka, A., Kobayashi, Y., Watanabe, T., Shimoyamada, H., Kuo, W. L., Li, R., Song, R., Bradley, W. A., and Gian Turco, S. H. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7488–7493
32. Lewis, G. F. (1997) Curr. Opin. Lipidol. 8, 146–153
Stimulation of the \textit{in Vivo} Production of Very Low Density Lipoproteins by Apolipoprotein E Is Independent of the Presence of the Low Density Lipoprotein Receptor

Bas Teusink, Arjen R. Mensenkamp, Hans van der Boom, Folkert Kuipers, Ko Willems, van Dijk and Louis M. Havekes

\textit{J. Biol. Chem.} 2001, 276:40693-40697.
doi: 10.1074/jbc.M106396200 originally published online August 23, 2001

Access the most updated version of this article at doi: 10.1074/jbc.M106396200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 31 references, 18 of which can be accessed free at
http://www.jbc.org/content/276/44/40693.full.html#ref-list-1